Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC-220 + itraconazole
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous (itraconazole)
01
Overview
This is a combination of **CC-220 (iberdomide)** and **itraconazole**. - **CC-220 (iberdomide)** is a novel immunomodulatory drug and cereblon modulator, developed for the treatment of relapsed/refractory multiple myeloma and systemic lupus erythematosus. It binds with high affinity to cereblon, a substrate receptor of the CRL4^CRBN^ E3 ubiquitin ligase, facilitating the ubiquitination and degradation of the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), which is believed to mediate its antitumor and immunomodulatory effects. - **Itraconazole** is a triazole antifungal agent used for the treatment and prophylaxis of various systemic and superficial fungal infections. It inhibits fungal 14α-demethylase (a CYP450 enzyme), disrupting ergosterol synthesis and compromising fungal cell membrane integrity.
- Other names
- iberdomide
02
Targets
CRBN (Cereblon)CYP51A1 (Sterol 14α-demethylase)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)PIK3R1 (Phosphatidylinositol 4-phosphate 3-kinase regulatory subunit alpha)6HB (SARS-CoV-2 spike protein HR1/HR2 six-helix bundle interface)STAT3 (Signal Transducer and Activator of Transcription 3)SMO (Smoothened)
Beyond the preview
Go deeper on CC-220 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC-220 + itraconazole.